HOXB13 and prostate carcinoma: In prostate cancer liver metastasis models driven by HoxB13, repeated systemic SCORT‐Cas13d‐gHoxB13 treatment significantly decreases HoxB13 expression, reduces metastasis, and extends mouse survival.